vs
Side-by-side financial comparison of DENNY'S Corp (DENN) and IOVANCE BIOTHERAPEUTICS, INC. (IOVA). Click either name above to swap in a different company.
DENNY'S Corp is the larger business by last-quarter revenue ($113.2M vs $86.8M, roughly 1.3× IOVANCE BIOTHERAPEUTICS, INC.). On growth, IOVANCE BIOTHERAPEUTICS, INC. posted the faster year-over-year revenue change (17.7% vs 1.3%). DENNY'S Corp produced more free cash flow last quarter ($16.0M vs $-61.9M). Over the past eight quarters, IOVANCE BIOTHERAPEUTICS, INC.'s revenue compounded faster (1001.6% CAGR vs -0.9%).
Denny's is an American table service diner-style restaurant chain. It operates over 1,400 restaurants in the United States, Canada, México, Puerto Rico, and several other international locations.
Iovance Biotherapeutics, Inc. is a biopharmaceutical startup based in San Carlos, California. The company works to develop tumor-infiltrating lymphocyte (TIL) therapies against cancer.
DENN vs IOVA — Head-to-Head
Income Statement — Q3 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $113.2M | $86.8M |
| Net Profit | $632.0K | — |
| Gross Margin | — | 67.4% |
| Operating Margin | 9.2% | -84.7% |
| Net Margin | 0.6% | — |
| Revenue YoY | 1.3% | 17.7% |
| Net Profit YoY | -90.3% | — |
| EPS (diluted) | $0.01 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $86.8M | ||
| Q3 25 | $113.2M | $67.5M | ||
| Q2 25 | $117.7M | $60.0M | ||
| Q1 25 | $111.6M | $49.3M | ||
| Q4 24 | $114.7M | $73.7M | ||
| Q3 24 | $111.8M | $58.6M | ||
| Q2 24 | $115.9M | $31.1M | ||
| Q1 24 | $110.0M | $715.0K |
| Q4 25 | — | — | ||
| Q3 25 | $632.0K | $-91.3M | ||
| Q2 25 | $2.5M | $-111.7M | ||
| Q1 25 | $326.0K | $-116.2M | ||
| Q4 24 | $6.8M | — | ||
| Q3 24 | $6.5M | $-83.5M | ||
| Q2 24 | $3.6M | $-97.1M | ||
| Q1 24 | $4.7M | $-113.0M |
| Q4 25 | — | 67.4% | ||
| Q3 25 | — | 43.0% | ||
| Q2 25 | — | 5.5% | ||
| Q1 25 | — | -0.8% | ||
| Q4 24 | — | 68.7% | ||
| Q3 24 | — | 46.2% | ||
| Q2 24 | — | -0.8% | ||
| Q1 24 | — | — |
| Q4 25 | — | -84.7% | ||
| Q3 25 | 9.2% | -140.7% | ||
| Q2 25 | 7.3% | -189.8% | ||
| Q1 25 | 4.7% | -245.8% | ||
| Q4 24 | 12.6% | -117.5% | ||
| Q3 24 | 10.5% | -152.1% | ||
| Q2 24 | 7.9% | -327.6% | ||
| Q1 24 | 9.1% | -16464.6% |
| Q4 25 | — | — | ||
| Q3 25 | 0.6% | -135.3% | ||
| Q2 25 | 2.1% | -186.2% | ||
| Q1 25 | 0.3% | -235.5% | ||
| Q4 24 | 5.9% | — | ||
| Q3 24 | 5.8% | -142.7% | ||
| Q2 24 | 3.1% | -312.2% | ||
| Q1 24 | 4.3% | -15800.8% |
| Q4 25 | — | — | ||
| Q3 25 | $0.01 | — | ||
| Q2 25 | $0.05 | $-0.33 | ||
| Q1 25 | $0.01 | $-0.36 | ||
| Q4 24 | $0.13 | $-0.24 | ||
| Q3 24 | $0.12 | $-0.28 | ||
| Q2 24 | $0.07 | $-0.34 | ||
| Q1 24 | $0.09 | $-0.42 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $297.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $-32.7M | $698.6M |
| Total Assets | $502.9M | $913.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $297.0M | ||
| Q3 25 | — | $300.8M | ||
| Q2 25 | — | $301.2M | ||
| Q1 25 | $1.1M | $359.7M | ||
| Q4 24 | $100.0K | $323.8M | ||
| Q3 24 | $2.9M | $397.5M | ||
| Q2 24 | $2.8M | $412.5M | ||
| Q1 24 | $2.8M | $356.2M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $270.6M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | $698.6M | ||
| Q3 25 | $-32.7M | $702.3M | ||
| Q2 25 | $-34.6M | $698.5M | ||
| Q1 25 | $-36.4M | $767.9M | ||
| Q4 24 | $-34.0M | $710.4M | ||
| Q3 24 | $-54.5M | $773.5M | ||
| Q2 24 | $-53.2M | $768.5M | ||
| Q1 24 | $-55.7M | $680.0M |
| Q4 25 | — | $913.2M | ||
| Q3 25 | $502.9M | $904.9M | ||
| Q2 25 | $491.1M | $907.4M | ||
| Q1 25 | $488.1M | $966.7M | ||
| Q4 24 | $496.3M | $910.4M | ||
| Q3 24 | $461.6M | $991.1M | ||
| Q2 24 | $459.9M | $964.3M | ||
| Q1 24 | $460.4M | $869.8M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $16.0M | $-52.6M |
| Free Cash FlowOCF − Capex | $16.0M | $-61.9M |
| FCF MarginFCF / Revenue | 14.1% | -71.3% |
| Capex IntensityCapex / Revenue | 0.0% | 10.7% |
| Cash ConversionOCF / Net Profit | 25.28× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-336.2M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $-52.6M | ||
| Q3 25 | $16.0M | $-78.7M | ||
| Q2 25 | $9.4M | $-67.4M | ||
| Q1 25 | $5.0M | $-103.7M | ||
| Q4 24 | $8.5M | $-73.3M | ||
| Q3 24 | $6.6M | $-59.0M | ||
| Q2 24 | $14.2M | $-98.4M | ||
| Q1 24 | $215.0K | $-122.3M |
| Q4 25 | — | $-61.9M | ||
| Q3 25 | $16.0M | $-89.5M | ||
| Q2 25 | — | $-74.9M | ||
| Q1 25 | — | $-109.9M | ||
| Q4 24 | — | $-77.5M | ||
| Q3 24 | — | $-61.3M | ||
| Q2 24 | — | $-98.9M | ||
| Q1 24 | — | $-126.5M |
| Q4 25 | — | -71.3% | ||
| Q3 25 | 14.1% | -132.7% | ||
| Q2 25 | — | -124.9% | ||
| Q1 25 | — | -222.8% | ||
| Q4 24 | — | -105.1% | ||
| Q3 24 | — | -104.6% | ||
| Q2 24 | — | -317.9% | ||
| Q1 24 | — | -17685.3% |
| Q4 25 | — | 10.7% | ||
| Q3 25 | 0.0% | 16.1% | ||
| Q2 25 | — | 12.4% | ||
| Q1 25 | — | 12.6% | ||
| Q4 24 | — | 5.7% | ||
| Q3 24 | 0.0% | 3.9% | ||
| Q2 24 | — | 1.4% | ||
| Q1 24 | — | 583.4% |
| Q4 25 | — | — | ||
| Q3 25 | 25.28× | — | ||
| Q2 25 | 3.79× | — | ||
| Q1 25 | 15.38× | — | ||
| Q4 24 | 1.26× | — | ||
| Q3 24 | 1.01× | — | ||
| Q2 24 | 3.97× | — | ||
| Q1 24 | 0.05× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
DENN
| Franchisor Owned Outlet | $57.4M | 51% |
| Royalty | $27.7M | 25% |
| Advertising | $18.6M | 16% |
| Occupancy | $7.7M | 7% |
| Initial And Other Fees | $1.7M | 1% |
IOVA
| Amtagvi | $64.9M | 75% |
| Proleukin | $21.9M | 25% |
